JIVI damoctocog alfa pegol 500 IU powder for injection vial with diluent syringe Australia - Inggeris - Department of Health (Therapeutic Goods Administration)

jivi damoctocog alfa pegol 500 iu powder for injection vial with diluent syringe

bayer australia ltd - damoctocog alfa pegol, quantity: 500 iu - injection, powder for - excipient ingredients: sucrose; calcium chloride dihydrate; polysorbate 80; glycine; sodium chloride; histidine - jivi, damoctocog alfa pegol, is a long-acting recombinant factor viii concentrate indicated for use in previously treated adults and adolescents (12 years of age and older) with haemophilia a for:,? routine prophylactic treatment to prevent or reduce the frequency of bleeding episodes,? on-demand treatment and control of bleeding episodes,? per-operative management of bleeding (surgical prophylaxis),jivi does not contain von willebrand factor, and therefore is not indicated in patients with von willebrand?s disease.

EPREX 1000 Israel - Inggeris - Ministry of Health

eprex 1000

j-c health care ltd - recombinant human erythropoietin - solution for injection - recombinant human erythropoietin 1000 iu / 0.5 ml - erythropoietin - erythropoietin - treatment of severe anemia associated with chronic renal failure, anemia in zidovudine treated hiv infected patients, anemia in cancer patients on chemotherapy.to increase the yield of autologous blood from patients in a predonation programme initiated to avoid the use of homologous blood. treatment is indicated in patients with moderate anemia (packed cell volume (pcv) approximately 33 to 39% , no iron deficiency) if blood conserving procedures are not available or insufficient either: a: when the scheduled major elective surgery requires a large volume of blood ( 4 or more units of blood for females or 5 or more units for males) or b: when the period necessary to obtain the required volume of autologous blood is too short. perisurgery: reduction of allogeneic blood transfusion in surgery patients : eprex is indicated for the treatment of anemic patients (hemoglobin 9-11 g/dl) scheduled to undergo elective, noncardiac, nonvascular surgery to reduce the need for allogeneic blood transfusions. eprex is indicated for patients at high risk for periopertive transfusions with significant, anticipated blood loss. eprex is not indicated for anemic patients who are willing to donate autologous blood. the safety of the perioperative use of eprex has been studied only in patients who are receiving anticoagulant prophylaxis. eprex is indicated before surgerios known be associated with excessive blood loss (at least 2 units ).

EPREX 2000 Israel - Inggeris - Ministry of Health

eprex 2000

j-c health care ltd - recombinant human erythropoietin - solution for injection - recombinant human erythropoietin 2000 iu / 0.5 ml - erythropoietin - erythropoietin - treatment of severe anemia associated with chronic renal failure, anemia in zidovudine treated hiv infected patients, anemia in cancer patients on chemotherapy.to increase the yield of autologous blood from patients in a predonation programme initiated to avoid the use of homologous blood. treatment is indicated in patients with moderate anemia (packed cell volume (pcv) approximately 33 to 39% , no iron deficiency) if blood conserving procedures are not available or insufficient either: a: when the scheduled major elective surgery requires a large volume of blood ( 4 or more units of blood for females or 5 or more units for males) or b: when the period necessary to obtain the required volume of autologous blood is too short. perisurgery: reduction of allogeneic blood transfusion in surgery patients : eprex is indicated for the treatment of anemic patients (hemoglobin 9-11 g/dl) scheduled to undergo elective, noncardiac, nonvascular surgery to reduce the need for allogeneic blood transfusions. eprex is indicated for patients at high risk for periopertive transfusions with significant, anticipated blood loss. eprex is not indicated for anemic patients who are willing to donate autologous blood. the safety of the perioperative use of eprex has been studied only in patients who are receiving anticoagulant prophylaxis. eprex is indicated before surgerios known be associated with excessive blood loss (at least 2 units ).

EPREX 4000 Israel - Inggeris - Ministry of Health

eprex 4000

j-c health care ltd - recombinant human erythropoietin - solution for injection - recombinant human erythropoietin 4000 iu / 0.4 ml - erythropoietin - erythropoietin - treatment of severe anemia associated with chronic renal failure, anemia in zidovudine treated hiv infected patients, anemia in cancer patients on chemotherapy.to increase the yield of autologous blood from patients in a predonation programme initiated to avoid the use of homologous blood. treatment is indicated in patients with moderate anemia (packed cell volume (pcv) approximately 33 to 39% , no iron deficiency) if blood conserving procedures are not available or insufficient either: a: when the scheduled major elective surgery requires a large volume of blood ( 4 or more units of blood for females or 5 or more units for males) or b: when the period necessary to obtain the required volume of autologous blood is too short. perisurgery: reduction of allogeneic blood transfusion in surgery patients : eprex is indicated for the treatment of anemic patients (hemoglobin 9-11 g/dl) scheduled to undergo elective, noncardiac, nonvascular surgery to reduce the need for allogeneic blood transfusions. eprex is indicated for patients at high risk for periopertive transfusions with significant, anticipated blood loss. eprex is not indicated for anemic patients who are willing to donate autologous blood. the safety of the perioperative use of eprex has been studied only in patients who are receiving anticoagulant prophylaxis. eprex is indicated before surgerios known be associated with excessive blood loss (at least 2 units ).

EPREX 10000 Israel - Inggeris - Ministry of Health

eprex 10000

j-c health care ltd - recombinant human erythropoietin - solution for injection - recombinant human erythropoietin 10000 iu/ml - erythropoietin - erythropoietin - treatment of severe anemia associated with chronic renal failure, anemia in zidovudine treated hiv infected patients, anemia in cancer patients on chemotherapy.to increase the yield of autologous blood from patients in a predonation programme initiated to avoid the use of homologous blood. treatment is indicated in patients with moderate anemia (packed cell volume (pcv) approximately 33 to 39% , no iron deficiency) if blood conserving procedures are not available or insufficient either: a: when the scheduled major elective surgery requires a large volume of blood ( 4 or more units of blood for females or 5 or more units for males) or b: when the period necessary to obtain the required volume of autologous blood is too short. perisurgery: reduction of allogeneic blood transfusion in surgery patients : eprex is indicated for the treatment of anemic patients (hemoglobin 9-11 g/dl) scheduled to undergo elective, noncardiac, nonvascular surgery to reduce the need for allogeneic blood transfusions. eprex is indicated for patients at high risk for periopertive transfusions with significant, anticipated blood loss. eprex is not indicated for anemic patients who are willing to donate autologous blood. the safety of the perioperative use of eprex has been studied only in patients who are receiving anticoagulant prophylaxis. eprex is indicated before surgerios known be associated with excessive blood loss (at least 2 units ).

Eposis 4000 I.U./0.4mL Solution For Injection (I.V./S.C.) Filipina - Inggeris - FDA (Food And Drug Administration)

eposis 4000 i.u./0.4ml solution for injection (i.v./s.c.)

new marketlink pharmaceutical corporation; distributor: new marketlink pharmaceutical corporation - recombinant human erythropoietin alfa - solution for injection (i.v./s.c.) - 4000 i.u./0.4ml

Eposis 10,000 I.U./mL Solution For Injection (I.V./S.C.) Filipina - Inggeris - FDA (Food And Drug Administration)

eposis 10,000 i.u./ml solution for injection (i.v./s.c.)

new marketlink pharmaceutical corporation; distributor: new marketlink pharmaceutical corporation - recombinant human erythropoietin alfa - solution for injection (i.v./s.c.) - 10,000 i.u./ml

Eposis 2000 I.U./0.5mL Solution For Injection (I.V./S.C.) Filipina - Inggeris - FDA (Food And Drug Administration)

eposis 2000 i.u./0.5ml solution for injection (i.v./s.c.)

new marketlink pharmaceutical corporation; distributor: new marketlink pharmaceutical corporation - recombinant human erythropoietin alfa - solution for injection (i.v./s.c.) - 2000 i.u./0.5ml

Reliferon 3 MillionIU / 0.5mL Solution for Injection IM/SC Filipina - Inggeris - FDA (Food And Drug Administration)

reliferon 3 millioniu / 0.5ml solution for injection im/sc

ambica int'l trading corp - recombinant human interferon alfa-2b - solution for injection im/sc - 3 millioniu / 0.5ml

Efotin 4000 IU/0.8mL Solution For IV Injection Filipina - Inggeris - FDA (Food And Drug Administration)

efotin 4000 iu/0.8ml solution for iv injection

n/a; importer: global pharmatrade; distributor: global pharmatrade - recombinant human erythropoietin alfa - solution for iv injection - 4000 iu/0.8ml